IBCN 2018: Mismatch Repair Deficiency in Upper Tract and Bladder Urothelial Carcinoma
Screening patients for Lynch syndrome is important including MMR deficiency. Moreover, determining response to treatments and assessment of treatments including immunotherapy, ie. PD-1 inhibitors is important to elucidate. Checkpoint inhibition appears effective in MMR deficient tumors. Further discovery and validation of screening methodologies underway with whole exome sequencing of tumors. Assessing the impact of screening methodologies and the impact of treatments according to MMR deficiency is also an area of needed research.
Presented by: Joost L. Boormans, Erasmus MC, Rotterdam, Netherlands
Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 16th Annual Meeting of the International Bladder Cancer Network (IBCN) October 11-13, 2018 - the Inntel Hotels Rotterdam Centre, Rotterdam, The Netherlands